"PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022" Published

From: Fast Market Research, Inc.
Published: Mon Apr 29 2013


GlobalData has released its new Country report, "PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022". Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agents: Bayer's Betaseron/Betaferon (IFNB-1b), Biogen's Avonex (IFNB-1a) and Merck's Rebif (IFNB-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/591919_pharmapoint_multiple_sclerosis_france_drug.aspx?afid=303
------------------------------------------------------------

The main driver of growth in this market is the launch of new MS DMTs, including oral agents that can be used as first-line therapy. Based on our primary research, French physicians are generally more receptive to products with novel mechanisms of action, which are likely to be priced higher than older drugs. In addition, with the high proportion of MS patients in France having a progressive MS subtype, the launch of new DMTs that specifically target SPMS and PPMS, such as masitinib and siponimod, will greatly increase treatment rates in these patients. France also has a lower-than-average rate of generic substitution compared with other countries, which will help off-patent drugs maintain their sales, although this may change during the forecast period due to government cost-cutting strategies.

Note: This is upcoming report and will be delivered within 24 hrs of the purchase (excluding weekends).

Scope

* Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in France from 2012-2022.
* Analysis of the impact of key events as well the drivers and restraints affecting France Multiple Sclerosis market.

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »